Stroquinan

Drug Profile

Stroquinan

Alternative Names: SP-8203; SP-8203 hydrochloride; SP8203HCL

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shin Poong Pharmaceutical
  • Class Neuroprotectants; Quinazolines
  • Mechanism of Action Reactive oxygen species inhibitors; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 May 2016 Phase-II clinical trials in Stroke (Adjunctive treatment) in South Korea (IV) (NCT02787278)
  • 28 Dec 2012 Shin Poong Pharmaceutical plans a phase I trial in Healthy volunteers in South Korea (NCT01757795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top